PAA 2022 , Human Trials , Covid , MND , Oncology , HVTL-1, K9 Phase III, page-619

With PK data Level 1 fight MND results due mid August and Level 2 due start October.

"A pharmacokinetic (PK) study of a new drug involves taking several blood samples over a period of time from study participants to determine how the body handles the substance. These studies provide critical information about new drugs."

The out come of that should be a given. All previous tests show MPL is well tolerated and absorbed. That should lead to more MND funding and fast tracking to phase 2. Yes I know it seems to be a bit contradicting to have "Fast tracking "in a PAA post.

With about 3mill on hand and the prospect of further MND funding PAA's finances should be ok in near future.

It seems to be agreed here by many including myself that the next 12 months should be a rewarding time for shareholders, the options could come into play. That could be about 17mill from memory, so hopefully we won't be forced into anything drastic.

Good luck to all